Study of Novel Treatment Combinations in Patients With Lung Cancer
Summary
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Timeline
- Start
- 2023-03-16
- Primary completion
- 2029-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Subject | Domvanalimab | Monoclonal antibody | — | Intravenous |
| Subject | Etrumadenant | Small molecule | — | Oral |
| Comparator | Nivolumab | Monoclonal antibody | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |